vs
Side-by-side financial comparison of TECHPRECISION CORP (TPCS) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
TECHPRECISION CORP is the larger business by last-quarter revenue ($7.1M vs $5.5M, roughly 1.3× Taysha Gene Therapies, Inc.). TECHPRECISION CORP runs the higher net margin — -20.8% vs -507.8%, a 487.0% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -6.9%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -9.2%).
TechPrecision Corp is a manufacturer of custom high-precision metal fabricated components and integrated systems, serving aerospace, defense, medical technology, renewable energy, and industrial end markets primarily across North America and Europe. It specializes in producing tight-tolerance, mission-critical parts that adhere to rigorous industry quality requirements.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
TPCS vs TSHA — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.1M | $5.5M |
| Net Profit | $-1.5M | $-27.9M |
| Gross Margin | 5.4% | — |
| Operating Margin | -19.1% | -516.0% |
| Net Margin | -20.8% | -507.8% |
| Revenue YoY | -6.9% | 171.3% |
| Net Profit YoY | -84.4% | -48.3% |
| EPS (diluted) | $-0.15 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.1M | $5.5M | ||
| Q3 25 | $9.1M | $0 | ||
| Q2 25 | $7.4M | $2.0M | ||
| Q1 25 | $9.5M | $2.3M | ||
| Q4 24 | $7.6M | $2.0M | ||
| Q3 24 | $8.9M | $1.8M | ||
| Q2 24 | $8.0M | $1.1M | ||
| Q1 24 | $8.6M | $3.4M |
| Q4 25 | $-1.5M | $-27.9M | ||
| Q3 25 | $825.0K | $-32.7M | ||
| Q2 25 | $-597.0K | $-26.9M | ||
| Q1 25 | $112.0K | $-21.5M | ||
| Q4 24 | $-799.0K | $-18.8M | ||
| Q3 24 | $-601.0K | $-25.5M | ||
| Q2 24 | $-1.5M | $-20.9M | ||
| Q1 24 | $-5.1M | $-24.1M |
| Q4 25 | 5.4% | — | ||
| Q3 25 | 27.1% | — | ||
| Q2 25 | 14.0% | — | ||
| Q1 25 | 22.0% | — | ||
| Q4 24 | 13.0% | — | ||
| Q3 24 | 11.3% | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 14.3% | — |
| Q4 25 | -19.1% | -516.0% | ||
| Q3 25 | 10.4% | — | ||
| Q2 25 | -6.3% | -1347.1% | ||
| Q1 25 | 3.9% | -930.5% | ||
| Q4 24 | -9.1% | -985.8% | ||
| Q3 24 | -5.5% | -1448.4% | ||
| Q2 24 | -16.8% | -1915.4% | ||
| Q1 24 | -28.6% | -713.3% |
| Q4 25 | -20.8% | -507.8% | ||
| Q3 25 | 9.1% | — | ||
| Q2 25 | -8.1% | -1353.6% | ||
| Q1 25 | 1.2% | -935.2% | ||
| Q4 24 | -10.5% | -929.0% | ||
| Q3 24 | -6.7% | -1427.5% | ||
| Q2 24 | -18.3% | -1882.0% | ||
| Q1 24 | -59.5% | -705.4% |
| Q4 25 | $-0.15 | $-0.08 | ||
| Q3 25 | $0.08 | $-0.09 | ||
| Q2 25 | $-0.06 | $-0.09 | ||
| Q1 25 | $0.01 | $-0.08 | ||
| Q4 24 | $-0.08 | $-0.07 | ||
| Q3 24 | $-0.06 | $-0.10 | ||
| Q2 24 | $-0.16 | $-0.09 | ||
| Q1 24 | $-0.59 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $50.0K | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $8.0M | $246.9M |
| Total Assets | $32.8M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $50.0K | $319.8M | ||
| Q3 25 | $220.0K | $297.3M | ||
| Q2 25 | $143.0K | $312.8M | ||
| Q1 25 | $195.0K | $116.6M | ||
| Q4 24 | $165.0K | $139.0M | ||
| Q3 24 | $132.0K | $157.7M | ||
| Q2 24 | $44.8K | $172.7M | ||
| Q1 24 | $138.0K | $124.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $3.0K | — | ||
| Q4 24 | $19.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $8.0M | $246.9M | ||
| Q3 25 | $9.1M | $219.0M | ||
| Q2 25 | $8.2M | $248.7M | ||
| Q1 25 | $8.7M | $55.1M | ||
| Q4 24 | $8.1M | $71.5M | ||
| Q3 24 | $8.9M | $88.8M | ||
| Q2 24 | $7.9M | $108.9M | ||
| Q1 24 | $7.8M | $53.8M |
| Q4 25 | $32.8M | $343.3M | ||
| Q3 25 | $33.8M | $316.6M | ||
| Q2 25 | $32.1M | $333.3M | ||
| Q1 25 | $33.5M | $138.4M | ||
| Q4 24 | $32.2M | $160.4M | ||
| Q3 24 | $35.0M | $180.2M | ||
| Q2 24 | $35.7M | $200.4M | ||
| Q1 24 | $34.7M | $153.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.0K | $-26.7M |
| Free Cash FlowOCF − Capex | $-827.0K | — |
| FCF MarginFCF / Revenue | -11.7% | — |
| Capex IntensityCapex / Revenue | 14.2% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-4.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.0K | $-26.7M | ||
| Q3 25 | $-1.1M | $-24.2M | ||
| Q2 25 | $646.0K | $-20.2M | ||
| Q1 25 | $396.0K | $-22.0M | ||
| Q4 24 | $-570.0K | $-18.3M | ||
| Q3 24 | $-532.0K | $-21.6M | ||
| Q2 24 | $107.0K | $-21.5M | ||
| Q1 24 | $-452.0K | $-19.8M |
| Q4 25 | $-827.0K | — | ||
| Q3 25 | $-2.1M | $-24.3M | ||
| Q2 25 | $-604.0K | — | ||
| Q1 25 | $-930.0K | — | ||
| Q4 24 | $-1.7M | $-18.3M | ||
| Q3 24 | $-2.0M | $-21.6M | ||
| Q2 24 | $-94.0K | $-21.7M | ||
| Q1 24 | $-900.0K | $-19.9M |
| Q4 25 | -11.7% | — | ||
| Q3 25 | -22.9% | — | ||
| Q2 25 | -8.2% | — | ||
| Q1 25 | -9.8% | — | ||
| Q4 24 | -22.9% | -905.5% | ||
| Q3 24 | -21.8% | -1210.9% | ||
| Q2 24 | -1.2% | -1951.9% | ||
| Q1 24 | -10.5% | -584.5% |
| Q4 25 | 14.2% | — | ||
| Q3 25 | 11.0% | — | ||
| Q2 25 | 16.9% | — | ||
| Q1 25 | 14.0% | — | ||
| Q4 24 | 15.4% | 0.1% | ||
| Q3 24 | 15.9% | 2.0% | ||
| Q2 24 | 2.5% | 18.1% | ||
| Q1 24 | 5.2% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | -1.31× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.54× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TPCS
| Defense | $6.7M | 94% |
| Other | $410.0K | 6% |
TSHA
Segment breakdown not available.
